by Jordana Choucair | Jan 25, 2022 | Life Sciences
Johnson & Johnson said it expects its COVID-19 vaccine to bring in up to $3.5 billion this year, up from $2.39 billion in 2021. Still, contributions from its COVID-19 vaccine are a small percentage of the company’s total revenue because it sells its vaccine at a...
by Jordana Choucair | Jan 25, 2022 | Life Sciences
Pfizer Inc. and BioNTech SE said they are testing a version of their COVID-19 vaccine that targets the Omicron variant. Pfizer said results are expected in the first half of the year so that an Omicron-specific vaccine is available “should it be needed.”...
by Jordana Choucair | Jan 24, 2022 | Life Sciences
The FDA is weighing whether to limit the authorization of monoclonal antibody treatments from Eli Lilly & Co. and Regeneron Pharmaceuticals Inc., which haven’t proved effective against the Omicron variant. According to a person familiar with the process,...
by Jordana Choucair | Jan 24, 2022 | Life Sciences
Pfizer Inc. CEO Albert Bourla said the drugmaker hopes to offer an annual COVID-19 vaccine because it “will not be a good scenario” if people have to get more frequent booster shots. He said Pfizer aims to develop a vaccine that “covers omicron and...
by Jordana Choucair | Jan 20, 2022 | Life Sciences
A new analysis by the Congressional Budget Office found that savings from generics have driven average prescription prices down in Medicare and Medicaid. Between 2018 and 2019, the average price for a generic prescription fell in both program while the use jumped from...
by Jordana Choucair | Jan 20, 2022 | Life Sciences
A group of 27 generic drugmakers agreed to manufacture Merck & Co.’s COVID-19 antiviral pill in an effort to supply more than 100 lower-income countries with the treatment. According to the United Nations-backed Medicines Patent Pool, the drug should be...
Recent Comments